Compare Moderna, Inc. (MRNA) vs USA Rare Earth Inc. Class A Common Stock (USAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs USA Rare Earth Inc. Class A Common Stock — how do they compare? Moderna, Inc. trades at $223.87 (market cap $86.33B), while USA Rare Earth Inc. Class A Common Stock trades at $10.18 (market cap $4.23B). The key difference: Moderna, Inc. is far larger — about 20.4× USA Rare Earth Inc. Class A Common Stock's market cap, and Moderna, Inc. is trading nearer its 52-week high, USA Rare Earth Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and USA Rare Earth Inc. Class A Common Stock for 0 Days on average.
| MRNA | USAR | |
|---|---|---|
Market Cap | $86.33B | $4.23B |
Volume | 13,361,426 | 13,677,660 |
Sector | Health | Basic Materials |
52-Week High | $226.30 | $33.68 |
52-Week Low | $22.36 | $10.32 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $82.48B | $2.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $226.30, up 5.88% with strong technical momentum as it joins the Nasdaq-100 index. Despite beating Q2 2026 EPS estimates, the company faces fundamental challenges with negative profitability margins (-142.58% net income margin) and declining revenue from pandemic peaks. Technical indicators show bullish momentum with price above key support levels, while analyst sentiment remains divided with a $115.70 consensus target well below current levels.
The outlook balances Nasdaq inclusion benefits against valuation concerns after a 500% 2026 rally. Investment opportunity lies in the cancer vaccine pipeline growth, while risks include sustained profitability challenges and high valuation multiples (P/S 38.5) that may not justify current price levels given declining revenue trends.
USA Rare Earth (USAR) trades at $11.265, down 4.7% today and near its 52-week low, reflecting persistent sector pressure. The company shows severe financial strain with a net income margin of -2,159.3% and negative cash flow from operations, though analyst consensus remains unanimously bullish with a $34.57 price target. Recent news highlights strategic investments in a $1.2 billion South Carolina facility and a $2.8 billion Brazil acquisition to build a mine-to-magnet supply chain, positioning it for long-term growth amid U.S. critical mineral initiatives.
The stock presents high risk due to extreme losses and cash burn but offers speculative upside if government funding and project milestones materialize. Key risks include execution challenges, reliance on future financing, and sector volatility. Investors should weigh the bullish analyst outlook against the company's current financial instability and macroeconomic headwinds affecting rare earth markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About USA Rare Earth Inc. Class A Common Stock
USA Rare Earth is building an integrated rare earth and permanent magnet supply chain spanning mining, metal and alloy production, and magnet manufacturing, with assets including the Round Top heavy rare earth deposit in Texas, a magnet manufacturing facility in Stillwater, Oklahoma, and metal-and-alloy producer Less Common Metals.
Read more on USAR →
